Last reviewed · How we verify
mFOLFOX 6
mFOLFOX6 is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
mFOLFOX6 is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer.
At a glance
| Generic name | mFOLFOX 6 |
|---|---|
| Also known as | Oxaliplatino + l-leucovorin + 5 Fluorouracile |
| Sponsor | Chungnam National University Hospital |
| Drug class | Combination chemotherapy regimen |
| Target | Thymidylate synthase (5-FU); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
mFOLFOX6 (modified FOLFOX6) is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, leucovorin (folinic acid) enhances 5-FU activity by stabilizing its binding to the enzyme, and oxaliplatin is a platinum agent that forms DNA cross-links to trigger cell death. This triplet combination is designed to provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Anemia
- Mucositis
- Fatigue
Key clinical trials
- Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer (PHASE2, PHASE3)
- Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression (PHASE2)
- Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer (PHASE2)
- Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer (PHASE3)
- Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer (PHASE3)
- INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer (PHASE2)
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations (PHASE3)
- Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |